不列颠哥伦比亚省温哥华（2022 年 11 月 30 日）——威克斯药业有限公司（“WEX”或“公司”）

Vancouver, BC (November 30, 2022) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that it has received authorizations for its Phase 2B Clinical Trial Applications from the regulatory authorities of China, Singapore, Taiwan, Korea, USA, and Canada.